Open-Label Continuous Administration Study With Adalimumab (D2E7) in Subjects With Rheumatoid Arthritis.
Phase of Trial: Phase III
Latest Information Update: 30 Mar 2010
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 09 Mar 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Nov 2005 New trial record.